Director, Translational Sciences — Dermatology

Biopharma Careers; Wilmington (DE); On-site; USD 120,000 - 170,000; Full time

Job summary

Incyte, headquartered in Wilmington, Delaware, is seeking a Translational Scientist to help formulate strategies for delivering our Dermatology, Inflammation and Auto-Immunity pipeline. The role emphasizes developing translational plans, delivering biomarker data, and communicating insights to guide clinical development.

The candidate will collaborate with discovery and clinical teams, manage external CROs, and contribute to decision-making with state-of-the-art technologies to advance novel

Qualifications

• Proven track record delivering biomarker strategies and analysis plans for clinical development.
• Ability to use multi-omics data to inform decisions in a matrix team.
• Strong written and oral communication for development teams and external experts.

Responsibilities

• Collaborate with drug discovery and clinical development to drive translational strategies.
• Deliver robust translational data supporting dermatology and IA I pipeline.
• Review, analyze, and interpret data from diverse sources; evaluate impact on drug development.
• Represent Translational Sciences with strategic direction to matrix partners and external experts.
• Document and communicate insights to the development team and medical community.

Skills

Biomarker strategies

Data analysis plans

Multi-omics decision making

Scientific communication

Independent contributor

Education

MD/PhD or PhD with 5+ years drug development experience

Job description

Incyte, headquartered in Wilmington, Delaware, is seeking a Translational Scientist to help formulate strategies for delivering our Dermatology, Inflammation and Auto-Immunity pipeline. The role emphasizes developing translational plans, delivering biomarker data, and communicating insights to guide clinical development.

The candidate will collaborate with discovery and clinical teams, manage external CROs, and contribute to decision-making with state-of-the-art technologies to advance novel